Celadon Pharmaceuticals Regulatory News (CEL)

1 Feb 2007 07:00

Celsis International PLC01 February 2007 STOCK EXCHANGE ANNOUNCEMENTFOR RELEASE: 1 February 2007 CELSIS INTERNATIONAL PLC ("Celsis" or "the Company") TOTAL VOTING RIGHTS 1 February 2007: Celsis International plc, the life sciences products andlaboratory services company, today announces that in conformity with theTransparency Directive's transitional provision 6 Celsis' capital consists of22,483,043 ordinary shares of 5p each ("Ordinary Shares") with voting rights.386,500 Ordinary Shares are held in treasury. Therefore, the total number ofvoting rights in Celsis is 22,096,543. The above figure (22,096,543 Ordinary Shares) may be used by shareholders as thedenominator for the calculations by which they will determine if they arerequired to notify their interest in, or a change to their interest in, Celsisunder the FSA's Disclosure and Transparency Rules. For further information please contact: Celsis International plc Tel: 01638 600 151Christian Madrolle, Finance Director & Company SecretaryJenny Parsons, Corporate Communications This information is provided by RNS The company news service from the London Stock Exchange